peripheral T-cell lymphoma

September 7, 2017

Verastem, with Phase 3 Results, to Request FDA Approve Oral Duvelisib to Treat Advanced CLL and SLL

News

Verastem’s duvelisib was seen to outperform Arzerra (ofatumumab) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced. ... Read more

May 12, 2017May 12, 2017

Managed Access Program to Provide European Peripheral T-cell Lymphoma Patients Access to Beleodaq

News

Europeans with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have no current alternative treatment options may soon get access to Onxeo‘s Beleodaq (belinostat), under a managed access program lauched by ... Read more

November 2, 2016November 2, 2016

Lymphoma Combo Therapy of Beleodaq and Checkpoint Inhibitors Shows Promise in Solid Tumors

News

Beleodaq (belinostat), an already approved drug for the treatment of peripheral T-cell lymphomas, has shown early promise in the treatment of other tumor indications when combined with immune checkpoint inhibitors, ... Read more

August 23, 2016August 23, 2016

Peripheral T-cell Lymphoma Therapy CD4CAR Granted Orphan Status by FDA

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to iCell Gene Therapeutics‘ Chimeric Antigen Receptor (CAR) engineered T-cells targeting CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). ... Read more

February 10, 2016May 13, 2016

NICE Updating Non-Hodgkin’s Lymphoma Guideline to Reflect New Treatment Options

News

The National Institute for Health and Care Excellence (NICE) is updating its position on the diagnosis and management of non-Hodgkin’s lymphoma, the most common type of lymphoma, to reflect recent improvements in treatment options ... Read more